Triple-Threat vaccine aims to shield seniors from three respiratory viruses
NCT ID NCT06984094
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests two new vaccines (SCB-1022 and SCB-1033) designed to protect against RSV, human metapneumovirus, and parainfluenza virus. About 612 healthy adults aged 60-85 will receive either a vaccine or a placebo. The main goal is to check safety and how well the vaccines trigger an immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
combination recombinant protein subunit vaccines (SCB-1022 and SCB-1033)
What this could lead to
If successful, these vaccines could protect older adults against three common respiratory viruses (RSV, hMPV, and PIV3) with a single shot.
What could go wrong
This is an early first-in-human study, so safety and immune response are still being tested. The vaccines may not work as hoped or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RSV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fusion Clinical Research
Adelaide, Southern Australia, 5067, Australia
-
Linear Clinical Research
Perth, Western Australia, 6009, Australia
-
Paratus Clinical Research
Melbourne, Victoria, 3070, Australia